Stock fact sheet · data as of
Organigram Global Inc. (OGI): fair value, margin of safety and Wheel Score
Ticker symbol OGI · Healthcare · Drug Manufacturers - Specialty & Generic · Canada · Value
Is OGI undervalued?
At 0.9650 (close of 5 Nov 2026), OGI trades 91% below the GLS average fair value of 11.09. That average comes from 5 models run on the latest filings, and 5 of them land above the current price. Margins of safety over 30% are the exception rather than the rule across the ~7,400 stocks we value each night, so the number earns Organigram Global Inc. the full Value points in the Wheel Score - and a closer look at what the market is pricing in.
There is a wide gap between Graham Number (4.30) and Graham Growth (26.41). When the models are this far apart the "fair value" is really a range, and the margin of safety above should be read with that range in mind.
Ranked against every other company we cover, OGI is clearly cheaper than it is fast-growing, so the nightly engine files it under Value (value score 95, growth score 63, out of 100).
Nine valuation models for OGI
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | 4.30 | +345% | The most a defensive investor pays for the earnings and book value per share |
| Graham Growth | 26.41 | +2636% | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields |
| Lynch | 11.54 | +1096% | EPS × the earnings growth rate (PEG of 1), growth capped at 25% |
| GLS Growth | 8.08 | +737% | EPS compounded ten years at the blended growth rate, discounted back at 15% a year |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | 5.13 | +432% | Earnings power value: current EPS capitalised at 9% with no growth |
| Zombie (liquidation) | 0.3654 | -62% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 0.0000 | -100% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Organigram Global Inc. scores 5 of 9 on the Piotroski F-score: a middling result that falls one point short of the "Piotroski 6 or more" Wheel Trade Filter. Some of the nine tests on profitability, leverage and efficiency are failed, so the accounts are worth a look before selling a put on the name. A GLS Moat score of 2.4/10 is a weak reading: the accounts do not show returns and margins that competitors have been unable to wear down, so the Moat part of the Wheel Score contributes little.
Returns on capital are thin or negative - ROIC -5.0%, ROE -5.1%, ROA -3.2% - with debt at 0.03 times equity and negative free cash flow.
Organigram Global Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain. Revenue comes mainly from International Business To Business 69%, Wholesale To Licensed Producers Revenue 25%, Direct To Patient Medical Revenue 6% (fiscal year FY2025).
Institutional ownership scores 1/10, insider activity 5/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 5 / 9 | ROIC | -5.0% |
|---|---|---|---|
| GLS Moat | 2.4 / 10 | ROE | -5.1% |
| Debt / equity | 0.03 | ROA | -3.2% |
| Free-cash-flow yield | -15.4% | Payout ratio | 0% |
| Institutions | 1 / 10 | Insiders · Congress | 5 · 5 / 10 |
Wheel Score 30: Weak
With a Wheel Score of 30 Organigram Global Inc. sits in the Weak band. It fails filter 4, financially healthy - Piotroski 5/9 (under 6); and filter 7, a premium worth selling - implied volatility 120% (over 80%); and filter 8, big enough - market cap $136M (under $1.0B); and filter 9, not a penny stock - price 0.96 (under $5); Premium (weak) is its weakest part.
Implied volatility is 120%, above the 80% ceiling of the Wheel Trade Filter on premium. The premium looks generous, but moves of that size can blow through any strike. Chain open interest is 5,063 contracts across all expiries - enough for the wheel at normal size.
Volume runs at 2.0M shares a day on a market cap of $136M, with a beta of 1.91 - a high beta, so the stock tends to move more than the market and a strike can be gapped through; the Stability part of the Wheel Score rates that weak.
| Filter | Wheel Trade Filter | Result | Detail |
|---|---|---|---|
| 1 | Options that actually trade | Passes | Listed options with 1,000+ contracts of open interest and 100+ traded a day |
| 2 | A real business, not a gamble | Passes | Profitable over the last twelve months - not a speculative stock, fund or note |
| 3 | Below fair value | Passes | Trading below the nine-model average fair value (margin of safety above 0) |
| 4 | Financially healthy | Fails | Piotroski 5/9 (under 6) |
| 5 | Can repay its debt | Passes | Long-term debt repaid from 3 years of operating cash flow or less (6 for real estate and utilities; banks and insurers are not judged on it) |
| 6 | No serious red flags | Passes | Red Flags score 60 or more out of 100 (earnings, margins, debt, analysts, filings and price checked the same way for every stock) |
| 7 | A premium worth selling | Fails | implied volatility 120% (over 80%) |
| 8 | Big enough | Fails | market cap $136M (under $1.0B) |
| 9 | Not a penny stock | Fails | price 0.96 (under $5) |
| How it ranks | Rating | From | |
|---|---|---|---|
| Value | Strong | 91% below fair value | |
| Premium | Weak | implied volatility 120% | |
| Moat | Weak | moat 2.4/10 | |
| Health | Fair | Piotroski 5/9 | |
| Red Flags | Strong | Red Flags score 90/100 | |
| Option trading | Weak | 208 contracts a day, 5,063 open interest | |
| Stability | Weak | beta 1.91, $136M company |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls: a stock must pass all 9 Wheel Trade Filters to score 70, and the score then ranks the ones that pass; the Sunday Scan is the top 10. It is updated nightly and is not a recommendation. How the Wheel Score works · the walkthrough lesson shows how it fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 15 Dec 2026 (before the open), 40 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Drug Manufacturers - Specialty & Generic
The 12 companies below are the closest to Organigram Global Inc. by market cap within the Drug Manufacturers - Specialty & Generic industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| DERM Journey Medical Corporation | 4.73 | - | - | 23Weak | $134M |
| CRDL Cardiol Therapeutics Inc. | 1.01 | 0.1498 | -574% | 10Weak | $122M |
| BGM BGM Group Ltd. | 9.12 | 6.82 | -34% | 12No options | $116M |
| ORGO Organogenesis Holdings Inc. | 0.8700 | 4.46 | +80% | 21Weak | $112M |
| SIGA SIGA Technologies, Inc. | 3.15 | 8.74 | +64% | 35Weak | $226M |
| GLAS Glass House Brands Inc | 2.58 | 54.75 | +95% | 30Weak | $227M |
| AAWH Ascend Wellness Holdings, Inc. | 0.3950 | 4.21 | +91% | 25No options | $80M |
| LFCR Lifecore Biomedical, Inc. | 6.44 | 0.9450 | -581% | 10Weak | $244M |
| ELTP Elite Pharmaceuticals, Inc. | 0.2400 | 6.18 | +96% | 33No options | $259M |
| CPIX Cumberland Pharmaceuticals Inc. | 4.44 | 22.07 | +80% | 26Weak | $67M |
| ZYBT Zhengye Biotechnology Holding Limited | 1.37 | 1.27 | -7% | 13No options | $65M |
| EBS Emergent BioSolutions Inc. | 5.90 | 45.07 | +87% | 36Weak | $303M |
Scan the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the top 10 stocks that pass all 9 Wheel Trade Filters, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about OGI
Is OGI undervalued right now?
By the GLS models, yes: at 0.9650 the stock is 91% below the average fair value of 11.09 (data as of 5 Nov 2026). Whether the discount is deserved is the question to research next.
What is the Wheel Score of OGI and what does it mean?
OGI scores 30 out of 100 (Weak) - it fails Wheel Trade Filters 4, 7, 8, 9. The Wheel Score ranks stocks for the wheel strategy - selling cash-secured puts, then covered calls if assigned - in two parts: the 9 pass/fail Wheel Trade Filters (busy options, a real business, below fair value, Piotroski 6 or more, debt it can repay, a Red Flags score of 60 or more, implied volatility of 25-80%, a $1 billion company, $5 a share) and a ranking of how strongly a stock passes on value, premium, moat, health, red flags, option trading and stability. A stock that fails any filter stays under 70; 70-84 is Good, 85 and above is Prime. The Sunday Scan is the top 10 that pass, sorted by Wheel Score.
What is the GLS fair value for OGI?
11.09 per share as of 5 Nov 2026 - the simple average of the 5 valuation models (out of nine: DCF, Graham Number, Graham Growth, Lynch, GLS Growth, 10 Cap, Payback Time, DDM and EPV) that produced a positive value. The models run every night on the latest filings; the Quote page lets you switch any of them off and add a margin of safety of your own.
When does Organigram Global Inc. report earnings next?
The next earnings report is due on 15 Dec 2026 (before the open), 40 days from the data date of 5 Nov 2026. The Calendars page lists every upcoming report with its time of day.
Does OGI have listed options, and how liquid are they?
Yes. The nightly snapshot found 4 listed contracts with 5,063 open interest across all expiries and implied volatility of 120% on the near-the-money contracts. The Options scanner lists the cash-secured put and covered call set-ups with premium and annualised yield worked out.